Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk

https://doi.org/10.20996/1819-6446-2016-12-4-424-429

Full Text:

Abstract

The problem of non-alcoholic fatty liver disease (NAFLD), which is an independent risk factor for a number of cardiovascular diseases (CVD), is considered. The high prevalence of cardiovascular risk factors is demonstrated in patients with NAFLD in Russian population. Common pathophysiological mechanisms of NAFLD and CVD (insulin resistance and excessive accumulation of lipids in the liver) are discussed. The "new" risk factors (thickening of the pericardial fat, endothelial dysfunction, thickening of the intima-media complex, increase in plasma level of C-reactive protein and others.) are found in patients with NAFLD, along with a greater prevalence of traditional factors of CVD risk (obesity, diabetes, metabolic syndrome and etc.). The relationship of NAFLD with atherosclerosis, dyslipidemia, features of bile acids metabolism in NAFLD and ability to influence these components are also considered.

About the Authors

O. M. Drapkina
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


O. N. Korneeva
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


References

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and theAmerican GastroenterologicalAssociation.Hepatology 2012;55:2005-2023.

2. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.

3. Korneeva ON, Drapkina OM, Bueverov SA, Ivashkin VT. Nonalcoholic fatty liver disease as a manifestation of the metabolic syndrome. Klinicheskie Perspektivy Gastroenterologii i Gepatologii 2005; 4: 21-4. In Russian (Корнеева О.Н. Драпкина О.М. Буеверов А.О. Ивашкин В.Т. Неалкогольная жировая болезнь печени как проявление метаболического синдрома. Клинические Перспективы Гастроэнтерологии и Гепатологии 2005; 4: 21-4).

4. Ivashkin VT, Drapkina OM, Maiev IV, et al. The prevalence of nonalcoholic fatty liver disease in patients of outpatient practice in the Russian Federation: results of the DIREG 2 trial. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii 2015; 6: 31-41. In Russian (Ивашкин В.Т., Драпкина О.М., Маев И.В., и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский Журнал Гастроэнтерологии, Гепатологии, Колопроктологии 2015; 6: 31-41).

5. De Alwis N.M., Day C.P. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008; 48 (Suppl. 1): 104-12.

6. Drapkina OM, Ivashkin VT. Epidemiological features of nonalcoholic fatty liver disease in Russia (the results of an open, multicentre prospective study observation DIREGL 01903 trial). The Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii 2014; 24 (4): 32-8. Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования наблюденияDIREGL 01903). Российский Журнал Гастроэнтерологии, Гепатологии, Колопроктологии 2014; 24(4): 32-8.

7. Korneeva OH, Drapkina OM. Nonalcoholic fatty liver disease in patients with metabolic syndrome syndrome. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii 2007; 17: 63-5. In Russian (Корнеева ОН, Драпкина ОМ. Неалкогольная жировая болезнь печени у пациентов с метаболическим синдромом синдромом. Российский Журнал Гастроэнтерологии, Гепатологии, Колопроктологии 2007; 17: 63-5).

8. Ivashkin VT, ed. Diagnosis and treatment of non-alcoholic fatty liver disease. Moscow: ROPIP; 2015. In Russian (Ивашкин В.Т., ред. Диагностика и лечение неалкогольной жировой болезни печени. М.: РОПИП; 2015).

9. Drapkina OM, Korneeva ON. Metabolic syndrome and cardiovascular disease in women. How big is the influence of gender? Serdtse 2011; 10 (4): 224-8. In Russian (Драпкина О.М., Корнеева О.Н. Метаболический синдром и сердечно-сосудистые заболевания у женщин.Насколько велико влияние пола? Сердце 2011; 10(4): 224-8).

10. Dam-Larsen S., Becker U., Franzmann M. B., et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scandinavian Journal of Gastroenterology 2009; 44(10): 1236-43.

11. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53:372-384

12. López-Suárez A, Guerrero JM, Elvira-González J, et al. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroenterol Hepatol 2011;23(11):1011-7.

13. Drapkina OM. Features of the course and treatment of hypertension in elderly patients with metabolic syndrome. Farmateka 2010; 8: 39-44. In Russian (Драпкина О.М. Особенности течения и лечения артериальной гипертензии у пожилых пациентов с метаболическим синдромом. Фарматека 2010; 8: 39-44).

14. Bachar GN et al. Epicardial adipose tissue as a predictor of coronary artery disease in asymptomatic subjects. Am J Cardiol. 15;110:534-8. 2012.

15. Natale F, Tedesco MA. Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, betterthanwaist circumference, carotid arterial stiffness in a large population of hypertensives. Eur J Echocardiogr 2009; 10:549-55.

16. Iacobellis G, Barbarini G, Letizia C, Barbaro G. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity 2014;22(2):332-6.

17. Drapkina OM., Korneeva ON, Ivashkin VT. A method of diagnosing insulin resistance: Patent 2553943 Russian Federation; published on 06.20.2015. Bulletin 2015; 17. In Russian (Драпкина ОМ., Корнеева О.Н., Ивашкин В.Т. Способ диагностики инсулинорезистентности: патент 2553943 Российская Федерация; опубликовано 20.06.2015. Бюллетень 2015;17).

18. Zyatenkova E.V., Drapkina O. M., Ivashkin V. Characteristics of vessels wall, myocardium and epicardial fat in patients with heart failure with preserved ejection fraction with and without metabolic syndrome.. Endosc Ultrasound 2014;3(Suppl 1):S1-2.

19. Drapkina OM, Zyatenkova EV. Evaluation remodeling of the cardiovascular system and epicardial fat thickness in patients with chronic heart failure and metabolic syndrome. Ter Arkhiv 2016; 88 (2): 64-70. In Russian (Драпкина О.М., Зятенкова Е.В. Оценка ремоделирования сердечно-сосудистой системы и толщины эпикардиального жира у пациентов с хронической сердечной недостаточностью и метаболическим синдромом. Терапевтический Архив 2016; 88(2): 64-70).

20. Gastaldelli A, Kozakova M, Højlund K, et al. Fatty liver is associated with insulin resistance,risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-44.

21. Balkau B, Lange C, Vol S, et al. Nineyear incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol 2010; 10: 56.

22. Calori G, Lattuada G, Ragogna F, et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011; 54: 145-52.

23. Drapkina OM, Deeva TA Ivashkin VT. Assessment of degree of endothelial function and apoptosis in patients with metabolic syndrome and nonalcoholic fatty liver disease. Ter Arkhiv 2015; 87 (5): 76-83. In Russian (Драпкина О.М.,Деева Т.А., Ивашкин В.Т. Оценка эндотелиальной функции и степени апоптоза у пациентов с метаболическим синдромом и неалкогольной жировой болезни печени. Терапевтический Архив 2015; 87(5): 76-83).

24. Lee YJ, Shim JY, Moon BS, et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 2012;57:196-203.

25. Kim BJ, Kim NH, Kim BS, Kang JH. The association between nonalcoholic fatty liver disease, metabolic syndrome and arterial stiffness in nondiabetic, nonhypertensive individuals. Cardiology 2012;123:54-61.

26. Salvi P, Ruffini R, Agnoletti D, et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens 2010;28(8):1699-707.

27. Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intimamedia thickness according to the presence of metabolic syndrome.Atherosclerosis 2009;204(2):521-525.

28. Ramilli S., Pretolani S., Muscari A., et al. Carotid lesions in outpatients with nonalcoholic fatty liver disease. World J Gastroenterol 2009; 15(38): 4770-4.

29. Yoneda M, Mawatari H, Fujita K, et al. High-sensitivity C-reactive protein is an independent clinical feature of non-alcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007;42:573-82.

30. Drapkina OM, Bueverova EL, Ivashkin VT. Atherogenic dyslipidemia and liver. Ateroskleroz i Dislipidemii 2010; 1: 25-31. In Russian (Драпкина О. М. Буеверова Е. Л. Ивашкин В. Т. Атерогенная дислипидемия и печень. Атеросклероз и Дислипидемии 2010; 1: 25-31).

31. Ivashkin VT. Nuclear receptors and liver disease. Part 2-I. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii 2010; 4: 7-15. In Russian (Ивашкин В.Т. Ядерные рецепторы и патология печени. Часть 2-я. Российский Журнал Гастроэнтерологии, Гепатологии, Колопроктологии 2010; 4: 7-15).

32. Korneeva ON, Drapkina OM. How to avoid the appointment of statin hepatotoxicity in patients with obesity and related liver disease? Focus on a combination of ursodeoxycholic acid and atorvastatin. Kardiovaskulyarnaya Terapiya i Profilaktika 2012; 11 (6): 81-4. In Russian (Корнеева О.Н., Драпкина О.М. Как избежать гепатотоксичности при назначении статинов у пациентов с ожирением и сопутствующей патологией печени? Фокус на комбинацию урсодезоксихолевой кислоты и аторвастатина. Кардиоваскулярная Терапия и Профилактика 2012; 11(6): 81-4).

33. Martsevich S.Y., Kutishenko N.P., Drozdova L.Y., et al. Study of ursodeoxycholic acid influence on efficacy and safety of statin therapy in patients with diseases of the liver, gall bladder and/or biliary tract (the RAKURS study). Rational Pharmacotherapy in Cardiology 2014;10(2):147-52. In Russian (Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю., и др., рабочая группа исследования РАКУРС «Изучение влияния урсодезоксихолевой кислоты на эффективность и безопасность терапии статинами у больных с заболеваниями печени, желчного пузыря и/или желчевыводящих путей (исследование РАКУРС)». Рациональная Фармакотерапия в Кардиологии 2014; 10 (2): 147-52).


For citation:


Drapkina O.M., Korneeva O.N. Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Rational Pharmacotherapy in Cardiology. 2016;12(4):424-429. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-4-424-429

Views: 478


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)